News | June 13, 2023
Biostar announces first patient enrolled for Phase 1 study of Utidelone Capsule
UTD2 is the world's first oral epothilone microtubule inhibitor
UTD2 is the world's first oral epothilone microtubule inhibitor
Survey of Unmet Needs in chronic myeloid leukemia (CML SUN) data signal need for amplified patient voice during treatment discussions that balance quality of life (QoL), efficacy, and tolerability goals across all lines of therapy
Coverage of CGHS cities has expanded from 25 cities in 2014 to 80 in 2023
The new API plant is set up to meet all domestic and international regulatory standards and will manufacture niche molecules that have a global requirement
The EU certification will support supplies of drug products registered in Europe, from this manufacturing site
The primary endpoint is to measure the change in liver stiffness measurement performed by transient elastography from Baseline to Week 52
Acquisition accelerates Cosette’s women’s health portfolio; with a differentiated, commercial stage, patent protected product
Lantern is receiving an exclusive and worldwide option to license intellectual property from Bielefeld University related to the collaboration and IP generated from the collaboration
Esomeprazole Magnesium for Delayed-Release Oral Suspension, 20 mg and 40 mg had annual sales of USD 42 mn in the United States (IQVIA MAT April 2023)
New facility will strengthen the security of supply for global pharmaceutical and biotech customers and will support the continued development and production of lifesaving clinical and commercial-scale therapeutics for patients worldwide.
Subscribe To Our Newsletter & Stay Updated
